Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy - PubMed (original) (raw)
Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy
D W Siemann et al. Int J Radiat Oncol Biol Phys. 1991 Feb.
Abstract
In the present investigations we evaluated the consequence of changing the cellular microenvironment on the treatment efficacy of the alkylating chemotherapeutic agent melphalan. Human A549 adenocarcinoma and mouse KHT/iv sarcoma cells were treated with melphalan under aerobic or hypoxic conditions at pH 6.6 or 7.4. Both low oxygenation and acidic pH individually were found to increase tumor cell killing by this chemotherapeutic agent. However, the magnitude of the enhanced toxic effect was greatest when hypoxic conditions and acidic pH were combined during treatment. For example, A549 cells treated with melphalan under hypoxic conditions at pH 6.6 were approximately 3 times more sensitive to this anticancer drug than were cells exposed in air at pH 7.4. Conditions of low oxygen and pH also increased the chemosensitization potential of the nitroimidazole misonidazole (MISO) when combined with this chemotherapeutic agent. Thus, when KHT/iv cells were treated with the combination of melphalan plus MISO, the resulting enhancement ratio increased from 1.8 to 2.5, when the pH maintained during the treatment was changed from physiologic (7.4) to acidic (6.6).
Similar articles
- Enhancement of chemotherapy and nitroimidazole-induced chemopotentiation by the vasoactive agent hydralazine.
Siemann DW. Siemann DW. Br J Cancer. 1990 Sep;62(3):348-53. doi: 10.1038/bjc.1990.295. Br J Cancer. 1990. PMID: 2206941 Free PMC article. - Potentiation of melphalan activity in the KHT sarcoma by the radiosensitizer RSU 1069.
Siemann DW, Maddison K, Wolf K. Siemann DW, et al. Int J Radiat Oncol Biol Phys. 1984 Sep;10(9):1657-60. doi: 10.1016/0360-3016(84)90522-4. Int J Radiat Oncol Biol Phys. 1984. PMID: 6548212 - Misonidazole chemosensitization of EMT6 spheroids to melphalan.
Horsman MR, Wood PJ, Brown JM. Horsman MR, et al. Radiother Oncol. 1989 May;15(1):103-14. doi: 10.1016/0167-8140(89)90123-0. Radiother Oncol. 1989. PMID: 2748937 - The advantageous use of hypoxic tumour cells in cancer therapy: identical chemosensitization by metronidazole and misonidazole at moderately elevated temperatures.
Urano M, Wong KH, Reynolds R, Begley J. Urano M, et al. Int J Hyperthermia. 1995 May-Jun;11(3):379-88. doi: 10.3109/02656739509022473. Int J Hyperthermia. 1995. PMID: 7636324 - pH, hypoxia and metastasis.
Hill RP, De Jaeger K, Jang A, Cairns R. Hill RP, et al. Novartis Found Symp. 2001;240:154-65; discussion 165-8. doi: 10.1002/0470868716.ch11. Novartis Found Symp. 2001. PMID: 11727927 Review.
Cited by
- Immunotherapy following regional chemotherapy treatment of advanced extremity melanoma.
Jiang BS, Beasley GM, Speicher PJ, Mosca PJ, Morse MA, Hanks B, Salama A, Tyler DS. Jiang BS, et al. Ann Surg Oncol. 2014 Aug;21(8):2525-31. doi: 10.1245/s10434-014-3671-0. Epub 2014 Apr 4. Ann Surg Oncol. 2014. PMID: 24700302 Free PMC article. Clinical Trial. - Minimally invasive intra-arterial regional therapy for metastatic melanoma: isolated limb infusion and percutaneous hepatic perfusion.
Han D, Beasley GM, Tyler DS, Zager JS. Han D, et al. Expert Opin Drug Metab Toxicol. 2011 Nov;7(11):1383-94. doi: 10.1517/17425255.2011.609555. Epub 2011 Oct 7. Expert Opin Drug Metab Toxicol. 2011. PMID: 21978383 Free PMC article. Review. - Hypoxia in melanoma: using optical spectroscopy and EF5 to assess tumor oxygenation before and during regional chemotherapy for melanoma.
Speicher PJ, Beasley GM, Jiang B, Lidsky ME, Palmer GM, Scarbrough PM, Mosca PJ, Dewhirst MW, Tyler DS. Speicher PJ, et al. Ann Surg Oncol. 2014 May;21(5):1435-40. doi: 10.1245/s10434-013-3222-0. Epub 2013 Aug 28. Ann Surg Oncol. 2014. PMID: 23982250 Free PMC article. - Optimizing regional infusion treatment strategies for melanoma of the extremities.
Coleman A, Augustine CK, Beasley G, Sanders G, Tyler D. Coleman A, et al. Expert Rev Anticancer Ther. 2009 Nov;9(11):1599-609. doi: 10.1586/era.09.126. Expert Rev Anticancer Ther. 2009. PMID: 19895244 Free PMC article. Review. - Preliminary studies with a new hypoxia-selective cytotoxin, KS119W, in vitro and in vivo.
Kim EY, Liu Y, Akintujoye OM, Shyam K, Grove TA, Sartorelli AC, Rockwell S. Kim EY, et al. Radiat Res. 2012 Sep;178(3):126-37. doi: 10.1667/rr2934.1. Epub 2012 Aug 3. Radiat Res. 2012. PMID: 22862779 Free PMC article.